Search results for: "Novo Nordisk"

(283 records)

Inoxell loses its senior management

Inhaled insulin in Phase III trials

Applications Published 26 September 2001

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the...

uk drug update

Applications Published 8 August 2001

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the...

Applications Published 8 August 2001

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the...

Drugs review of the year

The regulatory authorities are increasingly reluctant to approve products that offer few real benefits over therapies already on the market. Sarah Houlton reviews the new drugs...

New insulin device for better dose control from Novo Nordisk

Applications Published 16 May 2001

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the...

Applications Published 25 April 2001

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the...

Applications Publishes 18 April 2001

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the...

Trending Articles

  1. Nicox’s NCX 470 new drug application submitted in the United States by Kowa The submission is based on positive results from two Phase III clinical trials (Mont Blanc and Denali)
  2. Thermo Fisher's Patheon becomes exclusive third-party CDMO for KinetiSol technology The agreement will install KinetiSol Formulator equipment across Patheon's Bend and Cincinnati OSD sites, offering pharma customers an integrated development-to-commercial pathway for poorly soluble drug candidates
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Annex 1 at the transfer point: how to meet the evolving evidence challenge As Annex 1 raises expectations for contamination control, transfer-point evidence must become more dynamic, connected and defensible throughout the entire product lifecycle
  4. Sanofi offers EU commitments for flu vaccine disparagement claims Sanofi has proposed remedies to EU antitrust regulators after allegations it disparaged rival CSL Seqirus's Fluad vaccine in Germany and France since 2024
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Back to basics: a simple guide to checkweighing in pharmaceutical production Mettler-Toledo’s Miriam Krechlok tells Dr Kevin Robinson how checkweighing helps pharmaceutical manufacturers to verify product completeness, control fill levels and maintain compliance, safety and efficiency

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Digital The AI-driven biotech and China Medical System have struck a second collaboration in three months, targeting a mass-market CNS indication via a novel mechanism identified by...
Insilico Medicine and CMS deepen AI drug discovery tie-up with new CNS collaboration

Insilico Medicine and CMS deepen AI drug discovery tie-up with new CNS collaboration

Read more
Research & Development The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline...
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline

Read more
Manufacturing Piramal Pharma Limited (PPL) (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a...
Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones

Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones

Read more
Manufacturing The FDA's pre-licence inspection approval of WuXi Biologics' MFG8 facility will strengthen the CRDMO's commercial manufacturing network, supporting the global supply of a...
WuXi Biologics' Hebei facility secures FDA PLI approval for commercial autoimmune biologics manufacturing

WuXi Biologics' Hebei facility secures FDA PLI approval for commercial autoimmune biologics manufacturing

Read more
Manufacturing Boehringer Ingelheim has selected the osapiens HUB for Mobile Maintenance for its global, regulated manufacturing operations
Boehringer Ingelheim standardises plant maintenance globally with osapiens

Boehringer Ingelheim standardises plant maintenance globally with osapiens

Read more
Manufacturing With throughput up to 100 kg/h, the new twin-screw extruder brings lab-grade process understanding into pilot-scale production, enabling users to validate process parameters...
Brabender TwinLab B-TSE-S 30/40: Pilot-scale extrusion with lab-level insight

Brabender TwinLab B-TSE-S 30/40: Pilot-scale extrusion with lab-level insight

Read more
Dosage Forms While injection pens and weight-loss pills are gaining ground across the Western world, the debate focuses one-sidedly on the kilos and not on the body’s health and the...
Obesity medication: fast results … but at the expense of long-term health

Obesity medication: fast results … but at the expense of long-term health

Read more
Pharmaceutical The agreement will expand Teva’s biosimilars pipeline, with the company securing exclusive commercialisation rights for Polpharma Biologics’ proposed ocrelizumab biosimilar...
Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate

Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate

Read more